Updated Feb 12, 2025 18:11 IST
NATCO Pharma Q3 Results FY2025: The company reported a major setback in its consolidated revenue, which stood at Rs 475 crore for Q3 FY2025. This was a significant drop of over 37% compared to the Rs 759 crore reported in the same quarter of FY2024. The revenue shortfall has contributed to the negative market sentiment.
Following the earnings release, NATCO Pharma’s shares experienced a substantial drop, reaching an intraday low of Rs 475, marking a decrease of 37.4%.
NATCO Pharma Dividend 2025
The company informed in the BSE filing that the Board of Directors of the Company at their meeting held today have Declared 3rd interim dividend of Rs.1.50/- (Rupees One and Paise Fifty only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2024-25.
NATCO Pharma Dividend 2025: Record date
The company also shared in the BSE filing that the date for taking on record of its shareholders eligible for the purpose of payment of third interim dividend i.e., record date is fixed as Tuesday, 18th day of February 2025. The payment of said interim dividend will start from 28th February, 2025.
Strong decline in revenue and profit
The company reported a major setback in its consolidated revenue, which stood at Rs 475 crore for Q3 FY2025. This was a significant drop of over 37% compared to the Rs 759 crore reported in the same quarter of FY2024. The revenue shortfall has contributed to the negative market sentiment.
Profit after tax (PAT) takes a hit
PAT for the quarter also saw a sharp decline, registering a decrease of 37.8% at Rs 132.4 crore, compared to Rs 212.7 crore in the same quarter last year. The decline in both revenue and PAT highlighted the challenges faced by the pharmaceutical company during this period.
EBITDA and margin decline
NATCO Pharma’s EBITDA stood at Rs 38.8 crore in Q3 FY2025, reflecting an 85.5% year-over-year decline from Rs 268.1 crore reported in Q3 FY2024. The company’s EBITDA margin dropped drastically by 2717 basis points to just 8.2%, compared to 35.3% in the same quarter last year. The significant margin contraction further underlined the tough conditions the company faced this quarter.
NATCO Pharma’s Q3 results for FY2025 have marked a challenging quarter for the company, with significant declines in revenue, profit, and margins. Despite these setbacks, the company will need to recalibrate its strategy moving forward to recover from these drops and regain investor confidence. The market’s reaction reflects the concerns over NATCO’s performance in this quarter, with investors awaiting future updates on its recovery strategies.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)
End of article
